Insmed to Host Litigation Update Conference Call.Conference Call and Web-cast, December 7, 2006 at 11 a.m., ET RICHMOND, Va. -- Insmed, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :INSM INSM Initiative Neue Soziale Marktwirtschaft (German) INSM Integrated Network and Systems Management ) announced today that it will hold a conference call on Thursday, December 7 to discuss the outcome of the trial in the case of Genentech & Tercica v. Insmed. Insmed, the defendant in the patent infringement suit, will discuss the jury verdict which was returned on Wednesday, December 6. Among participants on the call will be Geoffrey Allan, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Insmed and Philip Young, executive vice president and CBO CBO See: Collateralized Bond Obligation. . Interested investors can listen to the call over the internet from Insmed's investor relations website at www.insmed.com or by dialling 866-316-1363 (domestic) or 913-312-1233 (international). A telephonic replay of the call will be available for one week at 888-203-1112 (domestic) or 719-457-0820 (international), pass code: 8482189. A web replay of the call will be available through the corporate website beginning at 6:00 p.m. About Insmed Insmed is a biopharmaceutical company focused on the development and commercialization of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit www.insmed.com. The company's leading product, IPLEX(TM), was approved as an orphan drug by the United States Food and Drug Administration United States Food and Drug Administration (FDA), n.pr a unit of the Public Health Service created to protect the health of the nation against impure and unsafe foods, drugs, and cosmetics. in December 2005 for the treatment of growth failure in children with severe primary IGF-I IGF-I see somatomedin C. IGF-I Insulin-like growth factor I, somatomedin-C A polypeptide hormone structurally similar to proinsulin, synthesized in the liver and fibroblasts, giving fibroblasts a paracrine function; serum levels correlate with deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion